Trump says tariffs will not be placed on gold, bringing relief to bullion markets
'Gold will not be Tariffed!' Trump said in a statement posted on his social media account. He gave no details.
The U.S. Customs and Border Protection had posted a ruling on its website on Friday saying that Washington might place the most widely traded gold bullion bars in the United States under country-specific import tariffs, which would have rocked the metal's global supply chains.
In response, a White House official told Reuters on Friday that the Trump administration was preparing an executive order 'clarifying misinformation' about tariffs on gold bars and other specialty products.
A U.S. gold tariff would have been especially harmful for Switzerland, a major refining and transit hub for gold. Trump's Monday post removes that concern.
Analysis: Gold and Trump's chaos are key to the TSX's stellar performance this year
'Delighted to hear the crisis has been averted,' said Ross Norman, an independent gold market analyst. 'It will come as an enormous relief to the bullion markets, as the potential for disruption was incalculable.'
U.S. gold futures dropped 2.4 per cent to $3,407 per ounce after Trump's post on Monday, reducing a premium over spot gold, the global benchmark, which fell 1.2 per cent to $3,357.
Shares of Barrick Mining ABX-T fell 2.8 per cent on Monday afternoon after the company posted quarterly results, while shares of Newmont NGT-T – the world's largest gold miner – were down slightly to $68.87. Both companies are major U.S. gold producers.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Globe and Mail
14 minutes ago
- Globe and Mail
oneZero makes the Inc. 5000 list of America's fastest-growing private companies for fourth consecutive year
NEW YORK, Aug. 12, 2025 /CNW/ -- Inc., the leading media brand and playbook for the entrepreneurs and business leaders shaping our future, today announced that oneZero Financial Systems (oneZero) has reached the 2025 Inc. 5000 list of the fastest-growing private companies in America. This is the fourth consecutive year that oneZero has made the prestigious ranking.
Globe and Mail
14 minutes ago
- Globe and Mail
Citizens Financial Group Names Aunoy Banerjee of Barclays as Chief Financial Officer
Citizens Financial Group, Inc. (NYSE: CFG) today announced the appointment of Aunoy Banerjee as Executive Vice President and Chief Financial Officer. He will serve on the company's Executive Committee and report to Chairman and CEO Bruce Van Saun. Banerjee joins Citizens from Barclays, where he currently serves as CFO of Barclays Bank PLC, leading a large, global, multifunctional team supporting multiple lines of business including U.S. Consumer, Global Corporate and Investment Banking, and Private Bank and Wealth Management. Banerjee will join Citizens on October 24. As previously announced, current CFO John Woods will depart the bank on August 15. Chris Emerson, EVP and Head of Corporate Planning & Enterprise Finance, will serve as CFO during the interim period. "Aunoy is a seasoned leader with a broad background and strong record of accomplishment over his career,' said Van Saun. 'His experience in leading finance functions at multiple large financial institutions and overseeing highly complex transformation and optimization programs positions him well to have immediate impact as we execute our ambitious growth and transformation agenda.' Said Banerjee: 'I could not be more excited to be joining Citizens to help drive sustainable growth and value for all of its stakeholders. The Bank has been on an exciting and transformational journey, and I look forward to partnering with Bruce and the leadership team to help take Citizens to the next level.' A 25-year financial services veteran, Banerjee will have responsibility for the Financial Planning and Analysis, Business Line Finance Groups, Controller, Investor Relations, Treasury, Tax, and Capital Management functions, as well as Property & Procurement. Prior to Barclays, Banerjee served in a number of increasingly responsible finance and transformation roles at State Street over eight years, most recently as Head of Investments & Third Party Management and Chair of State Street India. He also served as Chief Transformation Officer and prior to that ran Corporate FP&A and oversaw the CFO functions within its business units. He previously spent 11 years at Citi with several roles of increasing importance, including Business Unit CFO for Capital Markets and Securities Services, Finance Head of CCAR and Head of Corporate Forecasting and Planning. He began his professional career at General Electric as part of its Finance Management Leadership Program. Highlights of Banerjee's broad experience include overseeing a £1.1 trillion balance sheet at Barclays Bank PLC and co-leading the firm's sweeping investment bank simplification initiative. At State Street, he oversaw the firm's $100 billion-plus investment portfolio and its balance sheet funding position. Additionally, as Chief Transformation Officer, he led an enterprise-wide transformation aimed at simplifying operations, increasing operating margin and productivity, and boosting both organic and inorganic growth. Banerjee holds a Master of Business Administration degree from the University of Rochester Simon School of Business and a Bachelor of Science degree from St. Stephen's College at the University of Delhi. About Citizens Financial Group, Inc. Citizens Financial Group, Inc. is one of the nation's oldest and largest financial institutions, with $218.3 billion in assets as of June 30, 2025. Headquartered in Providence, Rhode Island, Citizens offers a broad range of retail and commercial banking products and services to individuals, small businesses, middle-market companies, large corporations and institutions. Citizens helps its customers reach their potential by listening to them and by understanding their needs in order to offer tailored advice, ideas and solutions. In Consumer Banking, Citizens provides an integrated experience that includes mobile and online banking, a full-service customer contact center and the convenience of approximately 3,100 ATMs and approximately 1,000 branches in 14 states and the District of Columbia. Consumer Banking products and services include a full range of banking, lending, savings, wealth management and small business offerings. In Commercial Banking, Citizens offers a broad complement of financial products and solutions, including lending and leasing, deposit and treasury management services, foreign exchange, interest rate and commodity risk management solutions, as well as loan syndication, corporate finance, merger and acquisition, and debt and equity capital markets capabilities. More information is available at or visit us on X (formerly Twitter), LinkedIn or Facebook . Cautionary Statement About Forward-Looking Statements This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements about our expectations regarding the appointment of a new Citizens chief financial officer. Any statement that does not describe historical or current facts is a forward-looking statement. These statements often include the words 'believes,' 'expects,' 'anticipates,' 'estimates,' 'intends,' 'plans,' 'goals,' 'targets,' 'initiatives,' 'potentially,' 'probably,' 'projects,' 'prospects,' 'outlook,' 'guidance' or similar expressions or future or conditional verbs such as 'may,' 'will,' 'likely,' 'should,' 'would,' and 'could.' Forward-looking statements are based upon the current beliefs and expectations of management, and on information currently available to management. Our statements speak as of the date hereof, and we do not assume any obligation to update these statements or to update the reasons why actual results could differ from those contained in such statements in light of new information or future events. We caution you, therefore, against relying on any of these forward-looking statements. They are neither statements of historical fact nor guarantees or assurances of future performance. More information about factors that could cause actual results to differ materially from those described in the forward-looking statements can be found under 'Risk Factors' in our Annual Report on Form 10-K for the year ended December 31, 2024 as filed with the United States Securities and Exchange Commission. View source version on
Globe and Mail
14 minutes ago
- Globe and Mail
Johnson & Johnson EVP Sells JNJ Shares Worth $3 Million
John C. Reed, Executive Vice President, Innovative Medicine and R&D of Johnson & Johnson (NYSE:JNJ), executed an open market sale of 19,137 shares as disclosed in a Form 4 filed July 18, 2025. Transaction summary Metric Value Shares traded 19,137 Transaction value $3.13 million, as reported in the SEC Form 4 filing dated July 18, 2025 1-year performance (as of July 18) 8% total return over the past year (calendar year basis) Key questions How does this transaction compare to John C. Reed's historical trading activity? This sale is smaller than Reed's historical median transaction size of 36,239 shares, and follows a recent trend of reduced trade volumes and more frequent selling over the past year, with only 20% of his trades classified as buys over the past 12 months. How does the transaction price relate to current market pricing? Shares were sold at an average price of $163.55, approximately 0.5% below the $164.36 closing price as of July 21, 2025, indicating the sale occurred at a slight discount to the latest market price. What is the context of this transaction in relation to Johnson & Johnson's recent performance? Johnson & Johnson shares delivered 8% total return in one year as of the transaction reporting date. The company maintains a large market capitalization and leadership in the healthcare sector, suggesting the sale does not coincide with pronounced negative price momentum. Company overview Metric Value Market capitalization $417.4 billion Revenue (TTM) $90.6 billion Net income (TTM) $22.7 billion Dividend yield 3.0% Company snapshot Johnson & Johnson generates revenue through two segments: innovative medicine (pharma) and medtech (medical devices). The company operates a diversified business model focused on research, development, manufacturing, and global distribution of healthcare products, with a balanced mix of prescription medicines and medical devices. Johnson & Johnson is a Dividend King, having increased its dividend for over 60 consecutive years. Foolish take Once known primarily for its consumer health brands such as Tylenol and Listerine, Johnson & Johnson made a major strategic move in 2023 when it spun off its consumer health business into a separate publicly-listed company, Kenvue. J&J is now a healthcare behemoth, with two diversified businesses that cover two of the most important areas of healthcare. Its innovative medicine segment focuses on oncology, immunology, and neuroscience, owns top medicine brands like Darzalex, Stelara, and Imbruvica, and accounted for 64% of J&J's total sales in fiscal 2024. Medtech, meanwhile, makes medical equipment and technologies for cardiology, surgery, and vision. Between the two businesses, J&J owns 26 products or platforms generating over $1 billion in annual sales each. Despite Stelara's loss of exclusivity, J&J continues to deliver. In its second quarter, J&J reported 5.8% growth in net sales. In innovative medicine, oncology continues to grow at a steady pace, while Spravato is growing rapidly. Sales from Spravato, a nasal spray for treatment-resistant depression in adults, jumped 53% in Q2. Strong Q2 performance and progress in new product pipeline even encouraged J&J management to boost its full-year guidance. It now expects operational sales (sales excluding the impact of currency) to grow by 4.8% at the midpoint versus its previous forecast of 3.8% and adjusted earnings per share by 8.7% at the midpoint versus 6.2%. I believe investors shouldn't read much into insider sales like Reed's transaction, and continue to buy and hold this magnificent dividend stock. Glossary Form 4: A required SEC filing disclosing insider trades by company officers, directors, or major shareholders. Open market sale: The sale of securities on a public exchange, rather than through private transactions or company programs. Insider trading activity: Buying or selling a company's stock by its executives, directors, or employees with access to nonpublic information. Median transaction size: The middle value of all transaction sizes, used to measure typical trade volume for an individual. Total return: The investment's price change plus all dividends and distributions, assuming those payouts are reinvested. Dividend yield: Annual dividend payments divided by the stock's current price, shown as a percentage. TTM: The 12-month period ending with the most recent quarterly report. Market capitalization: The total market value of a company's outstanding shares. Pharmaceuticals: Prescription drugs and medicines developed, manufactured, and sold by healthcare companies. Medtech: Medical technology products, including devices and equipment used in healthcare settings. Where to invest $1,000 right now When our analyst team has a stock tip, it can pay to listen. After all, Stock Advisor's total average return is 1,060%* — a market-crushing outperformance compared to 182% for the S&P 500. They just revealed what they believe are the 10 best stocks for investors to buy right now, available when you joinStock Advisor. See the stocks » *Stock Advisor returns as of August 11, 2025 Neha Chamaria has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Kenvue. The Motley Fool recommends Johnson & Johnson and recommends the following options: long January 2026 $13 calls on Kenvue. The Motley Fool has a disclosure policy.
